Loading...
•
Sep 30, 2022
Essa Pharma Q4 2022 Earnings Report
ESSA Pharma reported financial results for the fiscal fourth quarter and year ended September 30, 2022.
Key Takeaways
ESSA Pharma reported its financial results for the fiscal year ended September 30, 2022, highlighting the achievement of major milestones with Phase 1 data for EPI-7386 and a strong cash runway expected to fund operations through 2025.
Released Phase 1 monotherapy and combination data for EPI-7386, showing initial anti-tumor activity.
Observed notable PSA reductions in studies combining EPI-7386 with Xtandi® and Erleada®/Zytiga®.
Phase 1a monotherapy results showed tumor volume decreases and PSA declines in heavily pretreated mCRPC patients.
Cash runway is expected to fund operations and clinical programs through 2025.
Essa Pharma
Essa Pharma
Forward Guidance
ESSA Pharma anticipates a busy 2023 with advancement of clinical studies of EPI-7386 as a monotherapy and in combination with approved antiandrogens.